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A B S T R A C T
Purpose: GLUT1 deﬁciency syndrome is a treatable neurological disorder characterized by developmen-
tal delay, movement disorders and epilepsy. It is caused by mutations in the SLC2A1 gene inherited as an
autosomal dominant trait with complete penetrance, even if most detected SCL2A1 mutations are de
novo. Our aim is to present a wide series of Italian patients to highlight the differences among subjects
with de novo mutations and those with familial transmission.
Methods: We present clinical and genetic features in a series of 22 GLUT1DS Italian patients. Our patients
were classiﬁed in two different groups: familial cases including GLUT1DS patients with genetically
conﬁrmed affected relatives and sporadic cases with detection of SLC2A1 de novo mutation.
Results: We found remarkable differences in the severity of the clinical picture regarding the type of
genetic inheritance (sporadic versus familial): sporadic patients were characterized by an earlier
epilepsy-onset and higher degree of intellectual disability. No signiﬁcant differences were found in terms
of type of movement disorder, whilst Paroxysmal Exertion-induced Dyskinesia (PED) is conﬁrmed to be
the most characteristic movement disorder type in GLUT1DS. In familial cases the clinical manifestation
of the disease was particularly variable and heterogeneous, also including asymptomatic patients or
those with minimal-symptoms.
Conclusion: The ﬁnding of a ‘‘mild’’ phenotype in familial GLUT1DS gives rise to several questions: the real
incidence of the disease, treatment option with ketogenic diet in adult patients and genetic counseling.
 2014 British Epilepsy Association. Published by Elsevier Ltd. All rights reserved.
Contents lists available at ScienceDirect
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GLUT1 deﬁciency syndrome (GLUT1DS, OMIM 606777) is a
treatable neurological disorder caused by a deﬁciency of glucose
transporter type 1 (GLUT1) at the blood–brain barrier and in brain
cells which results in impaired glucose transport into the brain.
The clinical manifestations of GLUT1DS include developmental
delay, movement disorders, epilepsy and acquired microcephaly.
GLUT1DS was ﬁrst described in 1991 by De Vivo1 and seven
years later, a molecular basis for the defect in GLUT1-mediated* Corresponding author at: Department of Child Neurology and Psychiatry, ‘‘C.
Mondino’’ National Neurological Institute, Via Mondino 2, 27100 Pavia, Italy.
Tel.: +39 0382 380289; fax: +39 0382 380206.
E-mail address: pveggiot@unipv.it (P. Veggiotti).
http://dx.doi.org/10.1016/j.seizure.2014.11.009
1059-1311/ 2014 British Epilepsy Association. Published by Elsevier Ltd. All rights reglucose transport was found.2 GLUT1DS is still an often under-
diagnosed condition but it beneﬁts from rapid recognition because
an early introduction of the ketogenic diet (KD) could reduce the
frequency of seizures, the severity of the movement disorders, and
improve patients’ behavior and alertness.3
GLUT1DS is caused by mutations in the SLC2A1 gene (OMIM
138140) which maps to the short arm of chromosome 1 (1p35-
31.3).4 This is the only gene associated with GLUT1DS so far. The
condition is inherited as an autosomal dominant trait with
complete penetrance, however most detected SCL2A1 mutations
are de novo.5
We hereby present the clinical and genetic features in a series of
22 GLUT1DS Italian patients and compare their clinic-genetic
characteristics in order to ﬁnd any difference and signiﬁcant
features.served.
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2.1. Patients
56 Italian patients satisfying the clinical criteria for diagnosis of
GLUT1DS 6–9 underwent the genetics test from 2006 to 2014 at our
Institutes and 22 patients were found positive at SLC2A1 mutation.
Our study was approved by the Ethic Committee of our Institutes.
At recruitment the study sample includes 16 females and 6 males,
aged 2–57 (average 21.3) born to non-consanguineous parents.
In some previous papers the clinical, biochemical and genetic
features of patients #1, #2, #3 and #710–12 and patients #15 and
#1613 have already been described.
In 14/22 patients lumbar puncture (LP) was performed in the
fasting state (after 5–6 h of fasting), and the blood sample for
glucose measurement was obtained immediately before the
procedure to avoid stress-related hyperglycemia.7 A CSF-to-blood
glucose ratio below 0.6 was considered indicative for GLUT1DS.
In the remaining 8 patients, presenting high suggestive clinical
signs of the disease (intellectual disability, epilepsy and/or movement
disorder), LP was not performed for various reasons (non-compliance,
investigation failure, 5 patients were relatives of probands) and they
were directly submitted to SLC2A1 mutation analysis.
All the blood and CSF samples were collected, after obtaining
written informed consent, from patients and/or the parents. The
investigations fulﬁlled our institution’s ethical rules for human
studies.
All GLUT1DS patients were subjected to our diagnostic and
follow-up protocol including blood tests for the KD monitoring,
sleep EEG, neuropsychological assessments.7
All patients were classiﬁed in two different groups: familial
cases including GLUT1DS cases with genetically conﬁrmed affected
relatives and sporadic cases due to SLC2A1 de novo mutation.
We compared the two groups in order to identify some possible
clinical and genetic peculiarities.
2.2. Mutation analysis of SLC2A1
After obtaining written informed consent to genetic test
collected at ‘‘C. Mondino’’ National Neurological Institute, genomic
DNA from probands and relatives were extracted from peripheral
blood using standard procedures (Maxwell1 16 Blood DNA –
Promega, Milan, Italy).
All 10 exons of SLC2A1 gene were screened for sequence
variations by direct sequencing using the Big-Dye Terminator v. 3.1Table 1
Clinical and laboratory data in GLUT1DS sporadic patients.
Pt Gender Age Ratio HC IQ Spasticity Seizure Seizure Seiz
(y) (p) onset (m) typ
1 F 20 0.33 >508 <45 Y Y 6 ABS
MS
2 F 19 0.33 >508 <45 Y Y 3 FS, 
GTC
3 F 20 0.38 25–508 <45 Y Y 4 ABS
4 F 14 0.44 <258 53 Y Y 18 DS 
5 F 6 0.54 <258 76 N Y 11 GTC
6 F 10 0.34 <258 40 N Y 30 MA
ABS
7 F 13 NA <258 84 N Y 11 ABS
8 F 17 0.41 >508 62 Y Y 72 ABS
9 M 17 0.51 <258 57 N Y 72 CFS
10 M 11 0.51 <258 82 N Y 30 CFS
11 F 2 0.37 25–508 50 N Y 9 MA
Abbreviations: Pt, patient; F, female; M, male; Ratio, CSF/blood glucose ratio; NA, no
dyscognitive seizures; ABS, absence seizure; GTC, generalised tonic-clonic seizure; DR,
discharges; N, normal; MD, movement disorder; C, chronic; PED, paroxismal exertion-in
dystonia; c, choreoatetosis; Mi, migraine; Pr, Prognathism with dental malocclusion ansequencing kit (Applied Biosystems, Milan, Italy) and ABI 3130
Genetic Analyzer (Applied Biosystems, Milan, Italy). Each fragment
was sequenced on both strands. The alignment to reference
sequence (NG 008232.1) was performed using Sequencher 4.8
software.
The effect of the newly detected SLC2A1 mutations on protein
structure or function was analyzed with the prediction programs
ExPASy (http://www.expasy.org).
3. Results
The clinical signs and laboratory data are presented in Tables 1
and 2.
3.1. Clinical and genetic features in sporadic patients
The age range of sporadic cases (9 females and 2 males) at the
time of diagnosis and study enrollment was 2–20 (mean 13.5).
Their clinical signs and laboratory data are detailed in Table 1 and
summarized below.
Pregnancy, delivery and the neonatal period were uneventful in
all. Five patients (45%) had microcephaly (head circumference
below or equal to the 25th percentile for age at the time of
enrollment). Eight patients (73%) presented intellectual disability,
severe in 3 of these; 3 patients (27%) presented a borderline
Intellectual Quotient (IQ).
Epilepsy represented a main feature and the ﬁrst symptom in all
patients. Seizure onset was in the ﬁrst years of life (mean 24.1
months) and 6 patients (55%) developed a drug resistant condition.
Seizure types varied and included absence seizures (64%), usually
atypical or drug-resistant, dyscognitive seizures (36%), generalized
tonic-clonic (27%), myoclonic (27%), focal seizure without dyscog-
nitive features (18%), myoclonic-atonic (9%).
Ten patients (91%) presented a movement disorder (MD)
consisting of paroxysmal exercise-/stress-/fasting-induced MD
(73%) and/or paroxysmal kinesigenic MD (9%) and/or non-
paroxysmal MD (36%). In most cases it began in childhood (age
range: 8–168 months; mean 80.4 months) after seizure onset.
Dysarthria, reported to be a common sign in GLUT1DS,6,8 was
present in 55% of the patients, with halting speech, pauses,
articulation errors and dropping of word endings. Other associated
clinical signs included spasticity (45%), weakness on awakening or
in the fasting state (36%), migraine (27%), myoclonias (27%) and
prognathism with dental malocclusion (18%).ure DR EEG MD MD MD MD Other KD
e type subtype onset (m) response
 GTC Y SB G Y C a 12 Ds Pr
W Mi
EEG E
MD W
ABS,
 MS
Y SB G F Y C a c 8 Ds EEG
E MD
 FS MS Y SB G F Y C a 18 Ds Pr
W Mi
EEG E
MD W
Y SB F Y C a 20 Ds EEG E MD
 ABS N SB G Y PED d 36 W E MD W
S, DS, Y SB G F Y PED d 72 Ds W E MD W*
 Y SB G Y N N NA M NA
 N G Y PND a m 72 Mi E EEG
 N F Y PED d 168 Ds E MD
 N F Y PED c d 96 M MD
S NA SB G N – – – – E EEG
t available; Y, yes; N, no; HC, head circumference (percentiles); m, months; DS,
 drug resistance; SB, slow background activity; G, generalised discharges; F, focal
duced dyskinesia; PND, paroxysmal non exertion-induced dyskinesia; a, ataxia; d,
d/or supernumerary teeth; W, weakness; M, myoclonias; KD, ketogenic diet.
Table 2
Clinical and laboratory data in GLUT1DS familial patients.
Pt Gender Age Ratio CC IQ Spasticity Seizure Seizure Seizure DR EEG MD MD MD MD Other KD
(y) onset (m) type type subtype onset (m) response
12 F 5 0.39 <258 104 N Y NA DS, GTC, ABS N SB G F Y C a 16 – EEG E MD
13 M 10 0.47 25–508 75 N Y 72 DS Y SB F Y PED c 60 W Mi EEG
E MD IQ
14 F 43 NA >508 78 N Y 72 ABS N SB N – – – Mi Pr NA
15 M 35 NA >508 60 N Y 8 DS N N Y PED d/c 240 M NA
16 F 57 NA >508 74 N Y 60 ABS N N N – – – M NA
17 M 28 NA >508 85 N Y 48 ABS N N Y PED d/c 60 – NA
18 M 49 NA >508 75 N N – – – N Y PED
PND
d 144 W NA
19 F 10 0.38 <258 66 N N – – – N Y PED d/c 36 – MD
20 F 29 0.44 >508 55 N Y 12 ABS/GTC N SB G Y PED – NA – NA
21 F 24 NA >508 76 N Y 72 ABS N G N – – – – NA
22 F 27 NA >508 72 N Y 74 ABS N G Y PED – NA – NA
Abbreviations: Pt, patient; F, female; M, male; Ratio, CSF/blood glucose ratio; NA, not available; Y, yes; N, no; HC, head circumference (percentiles); m, months; DS,
dyscognitive seizures; ABS, absence seizure; GTC, generalised tonic-clonic seizure; DR, drug resistance; SB, slow background activity; G, generalised discharges; F, focal
discharges; N, normal; MD, movement disorder; C, chronic; PED, paroxismal exertion-induced dyskinesia; PND, paroxysmal non exertion-induced dyskinesia; a, ataxia; d,
dystonia; c, choreoatetosis; Mi, migraine; Pr, Prognathism with dental malocclusion and/or supernumerary teeth; W, weakness; M, myoclonias; KD, ketogenic diet.
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Table 3 summarizes the results of the SLC2A1 gene analysis.
Direct sequencing of SLC2A1 revealed 7 missense mutations (64%),
3 nonsense mutations (27%) and 1 splice site mutation (9%).
3.3. EEG and imaging
At the time of diagnosis, interictal EEG showed diffuse slowing
of background activity in 8 patients (73%), epileptiform discharges
with generalized 2–3.5 Hz spike-wave pattern in 8 patients (73%)
and focal/multifocal discharges in 6 patients (55%).
On MRI non-speciﬁc data were found in 4 patients and
included: moderate generalized cortical atrophy (#3), an arach-
noid cyst (#2), moderate atrophy of the cerebellar vermis (#4) and
delayed myelination (#11).
Two patients (#10, #11) in particular need to be mentioned;
their parents and relatives were negative to SLC2A1 gene mutation
but their siblings presented epileptic seizures (absences and
generalized tonic-clonic seizures) suggestive of epilepsy with
possible genetic origin.
The ﬁrst patient (#9) is a male presenting a normal IQ,
generalized tonic clonic epilepsy with onset at the age of 30
months, and PED (onset at 96 months); his CSF/blood glucose ratio
was 0.51 while direct sequencing of SLC2A1 revealed a missenseTable 3
Genetic data in GLUT1DS Italian patients.
Proband Protein
mutation
Gene
location
Type of
mutation
References
#1 W48X Exon 3 Nonsense Zorzi et al.10
#2 Q283X Exon 6 Nonsense Zorzi et al.10
#3 R126C Exon 4 Missense Zorzi et al.10
#4 P36R Exon 2 Missense Novel mutation
#5 c 1457delG_
1delG SPL
Intron-
Exon 10
Splice site Novel mutation
#6 R126C Exon 4 Missense Zorzi et al.10
#7 A275T Exon 6 Missense Weber et al.25
#8 R92W Exon 3 Missense Schneider et al.26
#9 R458W Exon 10 Missense Arsov et al.27
#10 R223W Exon 5 Missense Leen et al.30
#11 R249Afs131X Exon 6 Nonsense Novel mutation
F-1 (#12) R153C Exon 4 Missense Pascual et al.29
F-2 (#9,
#13, #14)
R458W Exon 10 Missense Arsov et al.27
F-3 (#15, #16) R153C Exon 4 Missense Pascual et al.29
F-4 (#17, #18) G91A Exon 3 Missense Gagliardi et al.13
F-4 (#19, #20,
#21, #22)
V165I Exon 4 Missense Urbizu et al.28mutation. His brother presented a generalized tonic-clonic epilepsy
with onset at 3 months and respondent to a single antiepileptic drug
(valproic acid). So far, after discontinuation of AED at 7 years of age,
his follow-up (current age 21) is completely negative for any type of
neurological disorder. In this person LP was not performed and
SLC2A1 gene analysis revealed no mutations (like in the parents).
The second patient (#10) is a female, presenting a mild MR,
myoclonic atonic epilepsy with early onset at 9 months and no
other clinical signs; her CSF/blood glucose ratio was 0.37, direct
sequencing of SLC2A1 revealed a nonsense mutation. In this
patient cerebral MRI showed delayed myelination, as previously
described in other GLUT1DS patients.14 Her brother is now 5 years
old, at the age of 3 he presented absence epilepsy with good
response to valproic acid. Now he is seizure free and he does not
present any neurological symptom after a follow-up of 2 years.
Also in this case LP was not performed and direct sequencing of
SLC2A1 revealed no mutation (like in the parents).
3.4. Clinical and genetic features in familial patients
Four males and seven females, aged from 5 to 57 (mean 28.8)
were found positive to SLC2A1 mutation in ﬁve families. The
clinical signs and laboratory data for this group are listed in Table 2
and presented below.
Pregnancy, delivery and the neonatal period were uneventful in
all. Two patients (18%) had microcephaly. IQ was normal in 2
patients (18%), borderline in 6 (55%) and indicative of mild
intellectual disability in 3 (27%).
Epilepsy was present in 9 patients (82%) with age of onset from
8 to 74 months (mean: 52.25 months). Only 1 patient presented a
drug-resistant condition (9%). Seizure types included absence
(64%), dyscognitive seizures (27%), generalized tonic-clonic (18%).
Three adult patients (#14, #21, #22) had epilepsy during infancy
respondent to common AEDs, but at the time of study enrollment
did not have any seizure.
MD was present in 8 patients (73%) with an age of onset from 16
to 240 months (mean: 92.6 months).
Associated clinical signs included weakness on awakening or in
the fasting state (18%), migraine (18%), myoclonias (18%) and
prognathism with dental malocclusion (18%).
3.5. Genetics
Table 3 and Fig. 1 summarize the results of the SLC2A1 gene
analysis in these ﬁve families. Direct sequencing of SLC2A1
detected missense mutations in all patients (100%).
Fig. 1. Pedigree of familial patients.
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In the SLC2A1-family patients, interictal EEG showed a lower
frequency of epileptiform and non-epileptiform abnormalities
compared to sporadic cases; in particular EEG showed diffuse
slowing of background activity in 4 patients (36%), generalized
spike and wave epileptiform discharges in 4 patients (36%) and
focal/multifocal discharges in 2 patients (18%). No abnormalities
were detected on neuroimaging.
3.7. Response to the ketogenic diet
13 patients underwent KD treatment (10 sporadic and 3 familial
patients). Patients were initially started on the classical 3:1
ketogenic ratio (3 g lipids: 1 g carbohydrates + proteins) but when
possible we reduced the ratio (in #11 to 1.8:1 ratio), maintaining
the same therapeutic efﬁcacy with stable beta-hydroxybutyrate
levels around 2 Mmol/l.
The efﬁcacy of KD treatment was noticeable. PED episodes
disappeared in a few weeks; this dramatic result was not replicated
for chronic MD like ataxia or chorea, although in 3 patients (#1, #2,
#3) a mild improvement was noticed.
Focal and/or generalized EEG abnormalities disappeared in 8/10
(80%) patients. We also noticed the disappearance of seizures in the 2
patients (#6, #10) who presented clinical seizures at the study
enrollment. As a result, 7 patients were able to come off AEDs after
approximately the ﬁrst year of treatment. Patient or parent-
perceived improvements in cognitive function, alertness and
activity after starting the KD were reported in 5 patients (37%).
An IQ improvement – albeit not statistically signiﬁcant – in patient
#12, is also worth noting. It is documented by an increase from 79 to
89 on the Wechsler Infant Intelligence Scale after 2 years on the KD.
The clinical improvement was maintained with time under KD
in all but 1 patient (#6), leading us to recommend permanent
continuation of this therapy as previously reported.14–16
4. Discussion
In this series of 22 GLUT1DS patients remarkable differences
were found in the severity of the clinical picture regarding the type
of genetic inheritance (sporadic versus familial).
In fact it was possible to detect the association of various severe
clinical manifestations and symptoms (epilepsy, MD and intellec-
tual disability) in almost all sporadic patients, thus suggesting a
more severe phenotype in this group; conversely in the familial
group the clinical expression of the disease was widely variableand heterogeneous. Moreover in familial patients the evolution
over the years seems to be spontaneously more favorable:
compared to sporadic patients they are affected by a more
‘‘benign’’ epilepsy, intellectual disability is less compromising and
other symptoms are less frequent, for this reason KD was tested
less in this group (3/11 patients).
The mental development was more compromised with a higher
intellectual disability in sporadic patients (sporadic mean IQ 58;
familial mean IQ: 74.5).
Regarding the epilepsy, all sporadic patients presented an
earlier epilepsy-onset (mean age onset 24.1 months versus familial
mean age onset 52.25 months) and higher tendency to become
refractory to conventional AEDs treatment (55% versus 9% in
familial group) even though in the second decade they experienced
a reduction in the intensity and frequency of their seizures. In
familial cases epilepsy (present in 82% of patients) was not a severe
disabling symptom, seizures were rare and disappeared in
adulthood.
Regarding MD we found no signiﬁcant difference between the
two groups (91% in sporadic and 73% in familial group), we noticed
only a mild later onset of MD in familial cases (92.6 months versus
80.4 months in sporadic group).
As outlined in literature PED also remains the most character-
istic MD type in GLUT1DS17,18 in our sample too. Furthermore
weakness and intermittent worsening of the MD during exercise or
fasting was a peculiarity in our case series19,20 (50% in sporadic and
18% in familial patients).
Nearly all our sporadic cases (91%) had both epilepsy and MD,
whereas familial cases presented only seizures (27%), or only MD
(18%) or both (55%).
In both sporadic and familial cases MD onset occured later than
seizures (in sporadic group 80.4 versus 24.1 months for seizures; in
familial group 92.6 versus 52.25 months) and it tended to replace
epilepsy over the years. Sporadic patients reported that MD was
the clinical symptom which most compromised the quality of life
before the introduction of KD. On the contrary in familial group MD
was not a severe disabling symptom, episodes were rare – even
without KD treatment – they persisted in adulthood but only after
a very prolonged physical activity.
Regarding the other symptoms we noticed that only in the
sporadic group spasticity (45%) and dysartric speech (55%) were
present. Neither microcephaly nor migraine was a key feature in
GLUT1DS. Prognathism was evident in 18% of sporadic patients and
in 18% of familial patients; even if it is not essential for the
GLUT1DS diagnosis we suggest keeping it in mind as a possible
gestalt sign of the disease.
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clinical severity, mutation type and glucose ratio or degree of
hypoglycorrhachia was detectable, as already reported in literature.21
With regard to treatment, we could not compare the two
groups: in familial patients KD was less tested (3/11) because of
the minor severity in their symptoms.
In all our sporadic patients KD was effective for epilepsy (when
present), in epileptic discharges and against MD. On the contrary
no improvement in the cognitive impairment was noticed even
after years of treatment, a possible explanation is that they only
underwent this etiological therapy in adulthood.
The clinical improvement was maintained with time in all but 1
patient (#6), leading us to recommend permanent continuation of
the KD therapy as previously reported.14–16
Patients #10 and #11 are genetically conﬁrmed GLUT1DS
patients, their siblings have a similar type of epilepsy but they are
negative for the SLC2A1 gene. Rushing to the conclusion that this is
a random association could be a general explanation. The possible
presence of an additional unknown gene involved in clinical
manifestation of the disease may be assumed.22,23
5. Conclusion
In conclusion, the present study delineates a wide heterogene-
ity in GLUT1DS, in particular our experience shows some
important differences between sporadic and familial inheritance
in terms of severity of the clinical picture. Familial patients allow
us to afﬁrm that in GLUT1DS a ‘‘mild’’ phenotype could be present.
This mild phenotype only shows a ‘‘benign’’ epilepsy, and/or a
slight MD, and/or a borderline IQ.
These ﬁndings necessarily raise several questions, ﬁrst of all the
real incidence of the disease: patients having a mild phenotype are
currently under-diagnosed.
Secondly we wonder if KD is suitable in asymptomatic or
minimally symptomatic patients bearing in mind that the diet, while
effective, has frequent difﬁculties in acceptance and compliance. No
suggestion is given in literature so far. This lack of experience
induces reserves in setting up such dietary therapy in adults in
which the anti-epileptic treatment achieves good results16 even if no
data are given about cognitive long-term outcome without
alternative fuel to the brain.
The marked differences in phenotypes among relatives or
patients sharing the same genetic mutation remain a challenging
issue to explain, for this reason giving a reasonably accurate
genetic counseling23 is difﬁcult.
A possible ﬁrst step to answer these questions could be the
creation of an international GLUT1DS registry in order to collect a
large series of patients to improve the knowledge regarding the
clinical variability of the disease.24
In patients without SLC2A1 mutation but with clinical
symptoms suggesting GLUT1DS a wide genetic screening should
be done in order to ﬁnd other genes associated with the disease.
The presence of other genes could enable us to explain the great
clinical variability found.
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